November 24, 2016 - By Peter Erickson
In a report revealed to investors and clients on today, Scotia Capital reconfirmed their “Outperform” rating on KP Tissue (TSE:KPT)‘s stock. The TP would indicate a potential upside of 13.79% from company’s current stock price.
Out of 4 analysts covering KP Tissue (TSE:KPT), 2 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 50% are positive. $18 is the highest target while $13.50 is the lowest. The $16.10 average target is 12.20% above today’s ($14.35) stock price. KP Tissue has been the topic of 16 analyst reports since August 13, 2015 according to StockzIntelligence Inc. TD Securities downgraded KP Tissue Inc (TSE:KPT) rating on Friday, October 21. TD Securities has “Hold” rating and $16 price target. TD Securities maintained KP Tissue Inc (TSE:KPT) rating on Friday, November 4. TD Securities has “Hold” rating and $16 price target. The stock has “Outperform” rating given by Scotia Capital on Friday, November 4. The firm earned “Buy” rating on Friday, August 12 by TD Securities. The stock of KP Tissue Inc (TSE:KPT) has “Outperform” rating given on Tuesday, September 1 by Scotia Capital.
About 3,010 shares traded hands. KP Tissue Inc (TSE:KPT) has risen 12.89% since April 20, 2016 and is uptrending. It has outperformed by 7.48% the S&P500.
KP Tissue Inc. is created to acquire, and its business is limited to holding, a limited partnership interest in Kruger Products L.P. . The company has a market cap of $130.28 million. KPLP is a tissue products supplier, which produces, distributes, markets and sells bathroom tissue, facial tissue, paper towels and napkins, for both the Consumer and the Away-From-Home (AFH) markets. It currently has negative earnings. KPLP operates through three divisions: consumer products sold through traditional retail channels, such as grocery stores, mass merchandisers, club stores, drug stores and convenience stores (Consumer); AFH, and Other.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.